Protein kinase Cf (PKCf) is phosphorylated at the activation loop and the turn motif (TM). However, the TM kinase and functional relevance of TM phosphorylation remain largely unknown. We demonstrate that PKCf TM is phosphorylated directly by the mTORC2 complex, and this phosphorylation is required for maintaining PKCf kinase activity and stability. Functionally, mTORC2 regulates the activity of Rho family of GTPases, and therefore the organization of the actin cytoskeleton, through the control of PKCf activity. Taken together, our findings identify PKCf as a novel substrate and downstream effector of mTORC2 signaling.
Introduction
PKCf, an atypical member of the PKC family, has been widely implicated in the regulation of cell polarity, tumorigenesis, and immune response [1, 2] . However, due to its unique domain composition and relatively low sequence similarity with conventional and novel PKCs, the molecular mechanism underlying the regulation of PKCf is less understood. The N-terminal regulatory domain in PKCf consists of a PB1 and a single cysteine-rich zinc-finger domain; as a consequence, PKCf is insensitive to diacylglycerol-and Ca
2+
-mediated activation due to lack of functional C1 and C2 domains [3] . In addition, PKCf differs in the phosphorylation sequence that are conserved among AGC (protein kinase A/G/C) kinase family members. The conventional and novel PKCs are known to be phosphorylated at three conserved phosphorylation sites, namely the activation loop (A-loop), the turn motif (TM), and the hydrophobic motif (HM) [4] . In the case of PKCf, only the A-loop and the TM are available for phosphorylation, while the HM is replaced by Glu, a phosphomimetic residue [3] . PDK-1 has been identified as the A-loop kinase for all PKC isozymes including PKCf [4, 5] . mTOR is a serine/threonine kinase which exists in two distinct functional complexes named mTOR complex 1 (mTORC1) and 2 (mTORC2) [6] . Both mTOR complexes contain multiple protein components with raptor and rictor functioning as the key nucleating members in mTORC1 and mTORC2, respectively. More recently, it has been shown that mTORC2 components are required for the phosphorylation of both the TM and the HM in conventional PKC isozymes and Akt, and the TM phosphorylation allows the maturation and stablization of the kinases [7] [8] [9] [10] . However, the nature of the TM kinase and the functional importance of TM phosphorylation in PKCf remain unknown.
In this study, we report the identification of mTOR in the mTORC2 complex as the upstream kinase that phosphorylates the TM of PKCf in vitro and in cells. We show that mTOR-mediated phosphorylation prevents the degradation of PKCf and promotes its kinase activity. Furthermore, PKCf functions downstream of mTORC2 to control actin cytoskeleton orgnization.
Results and Discussion
The TM phosphorylation of PKCf requires mTORC2 components
In our effort to study the regulation of PKCf, we found that the phosphorylation of PKCf at T560 (the TM) was completely lost in rictor knockout (Ric À/À ) MEF cells, whereas T410 (the A-loop) of PKCf was phosphorylated to a similar extent as in WT MEF cells (Fig 1A, lanes 1-4) . As a control, insulin-induced phosphorylation of Akt at S473, a known substrate of mTORC2, was absent in Ric À/À MEF cells as well. To confirm the specificity of rictor in regulating the TM phosphorylation of PKCf, a Myc-tagged rictor was re-introduced into Ric À/À MEF cells. As a consequence, the TM phosphorylation of PKCf, as well as insulin-induced phosphorylation of Akt at S473, was restored ( Fig 1A, lanes 5-6) . The level of T560 phosphorylation was lower in Myc-Rictor transfected Ric À/À MEF cells compared to WT MEF cells. This is likely due to the fact that only~30% of cells were transfected after transient transfection. In addition, we found that the TM phosphorylation of PKCf was absent in Ric
MEF cells regardless of serum or EGF stimulation, whereas the Aloop of PKCf was constitutively phosphorylated in both WT and Ric À/À MEF cells (supplementary Fig S1A and B) . As a control, the Myc-Rictor, were serum-starved for 4 h and subsequently treated with insulin (0.1 lM) for 15 min. Cells lysates were analyzed by immunoblotting using indicated antibodies. B The TM phosphorylation of PKCf is insensitive to the inhibition of PI3K activity. WT and Ric À/À MEF cells were treated with LY294002 (30 lM) in serum-free medium for 1 h. C PKCf is associated with the mTORC2 complex. 293T cell lysates were immunoprecipitated with either protein A/G beads alone (Mock, lane 1) or antibodies to rictor or raptor coupled to protein A/G beads (lanes 2-3, respectively). The immunoprecipitates and 5% of the input were analyzed by immunoblotting with indicated antibodies. D PKCf is phosphorylated by the mTORC2 complex in vitro. 293T cell lysates were immunoprecipitated with either protein A/G beads alone (Mock) or antibodies to rictor or raptor coupled to protein A/G beads. In vitro phosphorylation reactions were carried out by incubating the immunoprecipitates with partially purified PKCf as the substrate. E Knockdown of rictor but not raptor results in a decrease in TM phosphorylation of PKCf. Stable raptor, rictor, or mTOR knockdown colon cancer cells were analyzed for the phosphorylation of PKCf, Akt, and rpS6 using phospho-specific antibodies. F The TM of PKCf is dephosphorylated in cells treated with mTOR kinase inhibitors. 293T cells were treated with Torin1 (100 nM, lanes 1-4) or PP242 (1 lM, lanes [5] [6] [7] [8] for the indicated time.
Source data are available online for this figure.
EMBO Interestingly, PKCf remained phosphorylated after serum starvation for 4 h and growth factor treatment had no obvious effect on stimulating the phosphorylation at either the A-loop or the TM of PKCf in WT MEF cells. To further determine if alteration of PI3K activity affects the phosphorylation of PKCf, MEF cells were treated with LY294002 for 1 h. As expected, the phosphorylation of Akt was abolished upon inhibition of PI3K (Fig 1B) . However, the TM phosphorylation of PKCf remained largely unchanged whereas the A-loop phosphorylation was decreased (Fig 1B) . These data suggest that the A-loop phosphorylation of PKCf is sensitive to PI3K as previously reported [5, 11] , however, to a less extent compared to Akt. More importantly, the TM phosphorylation of PKCf is insensitive to PI3K but requires the expression of rictor. This constitutive nature of TM phosphorylation may suggest a co-translational mechanism that has been reported for mTORC2-mediated TM phosphorylation of Akt [12] .
Identification of PKCf as a novel substrate of mTOR in the mTORC2 complex
Since rictor is a key component in the mTORC2 complex, we tested the hypothesis that PKCf TM is phosphorylated by mTOR in the mTORC2 complex. Co-immunoprecipitation experiments showed that PKCf interacted with rictor and mTOR in mTORC2, but not raptor in mTORC1 ( Fig 1C, lanes 2-3) . Moreover, PKCf was phosphorylated in vitro at T560 by mTOR in the complex with rictor ( Fig 1D,  lane 2) , whereas the raptor-mTOR complex was unable to phosphorylate PKCf (Fig 1D, lane 3) , suggesting that the T560 site is a specific substrate of mTORC2. We next tested whether silencing mTORC2 components affects the TM phosphorylation of PKCf in three different colon cancer cell lines. Indeed, PKCf phosphorylation at T560, as well as Akt phosphorylation at S473, was largely abolished in rictor and mTOR knockdown cells (Fig 1E) . In contrast, the TM phosphorylation was not affected by silencing raptor, thus confirming the specificity of mTORC2. As a control, the phosphorylation of S6, a substrate of S6 kinase, was decreased in raptor and mTOR knockdown cells (Fig 1E) . Furthermore, the A-loop phosphorylation of PKCf remained unchanged in raptor, rictor, or mTOR knockdown cells, suggesting that the A-loop of PKCf is not regulated by either mTOR complex.
Finally, we examined the phosphorylation of PKCf in cells treated with mTOR kinase inhibitors. Inhibition of mTOR activity led to complete dephosphorylation of T560 in PKCf, while had no effect on T410 phosphorylation. The phosphorylation of Akt at S473 was dephosphorylated in cells treated with mTOR inhibitors as well ( Fig 1F) . Since PKCι, another member of the atypical PKC family, is highly homologous to PKCf, we also determined if PKCι TM is phosphorylated by mTORC2. Similar to PKCf, the TM phosphorylation of PKCι was completely lost in mTOR inhibitor-treated 293T cells whereas the A-loop was not affected (supplementary Fig S1C) . Thus, PKCι TM (T564 in human PKCι) is also a substrate of mTORC2. However, we did not detect PKCι expression (the mouse homologue is also known as PKCk) in WT or Ric À/À MEF cells using the PKCι/k-specific antibody. Results shown in all subsequent experiments performed in MEF cells are considered PKCf-specific. Although earlier studies have suggested that PKCf TM is phosphorylated via autophosphorylation [13] , our findings provide direct evidence that mTORC2 is responsible for phosphorylating the TM of atypical PKCs, including PKCf and PKCι.
The TM phosphorylation is a key determinant of PKCf kinase activity
We next determined whether the TM phosphorylation is required for PKCf activity. Although PKCf is basally phosphorylated at both the A-loop and the TM (Fig 1) , mutating either site to Ala (T410A or T560A) largely had not effect on the phosphorylation at the other site (Fig 2A) , thus confirming that the A-loop and the TM phosphorylation are independently mediated by two kinases. The activity of PKCf expressed in Ric À/À MEF cells was markedly Cell lysates were immunoprecipitated with the PKCf antibody and the kinase activity was assessed using MBP as the substrate. The level of MBP phosphorylation catalyzed by WT PKCf under control condition was set to 1 and all other conditions were normalized accordingly. Total MBP in each reaction was visualized on the membrane by Ponceau S staining. C Phosphorylation of PKCf at both T410 and T560 sites are required for its kinase activity. 293T cells transfected with vector, Flag-PKCf, Flag-PKCf/ T410A, Flag-PKCf/T410E, Flag-PKCf/T560A, or Flag-PKCf/T560D were serum starved overnight and subsequently treated with insulin for 15 min. Cell lysates were immunoprecipitated with Flag beads and the kinase activity was determined using MBP as the substrate.
Source data are available online for this figure. ª
decreased as the result of loss of TM phosphorylation (Fig 2B) . Moreover, similar to the A-loop mutant T410A, the TM phosphorylation-deficient mutant (T560A) was inactive, whereas the phospho-mimetic mutants T410E and T560D were equally active in vitro (Fig 2C) . There was a modest increase in WT PKCf activity upon insulin treatment (Fig 2B and C) . However, insulin had no effect on stimulating the activity of phosphorylation-deficient mutants, and the activity of phospho-mimetic mutants was similar to that of WT PKCf after insulin treatment (Fig 2C) . Collectively, our data show that loss of phosphorylation at the TM has a similar EMBO reports mTORC2 phosphorylates the turn motif of PKCf Xin Li and Tianyan Gao detrimental effect on the kinase activity of PKCf as losing phosphorylation at the A-loop. Thus, phosphorylation at both sites is required for PKCf activation.
The TM phosphorylation controls the protein stability and ubiquitination of PKCf
The phosphorylation of Akt and conventional PKC isozymes has been implicated in maintaining the protein stability [7] . It remains unknown whether the phosphorylation of PKCf controls its stability in cells. Since inhibition of HSP90 disrupts proper folding of multiple protein kinases including PKC isozymes [7] , we first examined the rate of PKCf degradation in the presence of HSP90 inhibitor, 17-AAG. The WT PKCf was a very stable protein even in cells treated with 17-AAG (Fig 3A) . However, loss of phosphorylation at the TM drastically reduced the half-life of PKCf, whereas the phosphorylation-deficient mutation at the A-loop had no effect on PKCf stability (Fig 3A and B) . Consistent with our finding that PKCf was basally phosphorylated at both the TM and the A-loop in cells, the phospho-mimetic mutants were equally stable as WT PKCf (Fig 3C) . In addition, the degradation of endogenous PKCf in Ric À/À MEF cells was significantly faster compared to that of WT MEF cells (Fig 3D  and E) . A similar decrease in Akt stability was observed in Ric À/À MEF cells (Fig 3D) [7] . Furthermore, loss of TM phosphorylation in PKCf drastically increased the level of ubiquitination suggesting faster turnover of the protein (Fig 3F, lanes 3-4) . The ubiquitination of T560D mutant was markedly lower than that of T560A but slightly higher compared to WT PKCf (Fig 3F, lanes 5-6) . This is likely because the phospho-mimetic residues are usually not perfect substitutions for phosphate groups. More importantly, the ubiquitination of PKCf expressed in Ric À/À MEF cells was largely increased as well (Fig 3G) . Taken together, our data demonstrate that mTORC2-mediated TM phosphorylation plays a critical role in stabilizing PKCf and lack of TM phosphorylation leads to increased ubiquitination and degradation of PKCf.
PKCf functions downstream of mTORC2 to control actin cytoskeleton organization
In mammalian cells, actin cytoskeleton reorganization is a dynamic and complex process that is orchestrated by activation of Rho family small GTPases, particularly Rho, Rac, and Cdc42. Previous studies have shown that mTORC2 modulates actin cytoskeleton [14] . However, the underlying molecular mechanism is less clear. We found that the morphology and the organization of actin cytoskeleton in WT and Ric À/À MEF cells showed striking differences. Specifically, Xin Li and Tianyan Gao mTORC2 phosphorylates the turn motif of PKCf EMBO reports when adhered to fibronectin-coated coverglasses, the formation of lamellipodia was readily observed in WT MEF cells which coincided with cortical organization of actin (Fig 4A) . Ric À/À MEF cells generally showed elongated and more spindle-like morphology associated with abundant actin stress fiber formation, however, apparently lacking lamellipodia (Fig 4B) . More examples of WT and Ric
MEF cells are shown in supplementary Fig S2. The percentage of cells with lamellipodia and cortical actin organization was 73.6% and 18.4% in WT and Ric À/À MEF cells, respectively, whereas stress fibers were observed in other cells (Fig 4C) . Since actin cytoskeleton organization is directly controlled by Rho family small GTPases [15] , we next determined if the activation of these GTPases is affected by rictor and PKCf. As shown in Fig 4D, the amount of activated Rac1 and Cdc42 was decreased by 90% and 50%, respectively, in Ric À/À MEF cells compared to WT cells. A similar decrease in Rac1 and Cdc42 activation was observed when Pkcf was knocked down in WT MEF cells. Consistent with the notion that RhoA activation is associated with stress fiber formation [15] , the amount of activated RhoA was markedly increased in Ric À/À and Pkcf knockdown MEF cells (Fig 4D) .
To determine if decreased PKCf activity in Ric À/À MEF cells contributes to altered actin cytoskeleton organization, we overexpres- EMBO reports mTORC2 phosphorylates the turn motif of PKCf Xin Li and Tianyan Gao sed EGFP-T560D in these cells. Indeed, the cortical organization of actin and lamellipodia formation were largely restored in cells expressing T560D PKCf whereas stress fibers remained in untransfected cells (Fig 5A and B) . As a control, overexpression of EGFP-T560A mutant in Ric À/À MEF cells had little effect on promoting lamellipodia formation (Fig 5C-D Rac1 and Cdc42 activation and normalized the activity of RhoA (Fig 5F and G) . In marked contrast, overexpression of T560A mutant had no effect on the activation of Rac1, Cdc42, or RhoA in Ric À/À MEF cells (supplementary Fig S4) . Collectively, these results demonstrate that PKCf is likely the downstream effector of rictor in controlling actin cytoskeleton rearrangement by modulating the activity of Rho family small GTPases. Recent studies have placed rictor and mTORC2 at the forefront of tumor initiation and progression. Identification of PKCf as a substrate of mTORC2 to control lamellipodia formation and cytoskeleton organization suggests that PKCf may play a role in regulating tumor cell migration and metastasis downstream of mTOR. Indeed, PKCf has been linked to rictor-dependent breast cancer metastasis [16] . A recent study has identified lethal giant larvae 2 (LLGL2) as a substrate of atypical PKCs to regulate cell migration [17] . By elucidating the role of TM phosphorylation, our study demonstrates that the constitutive phosphorylation of PKCf at the TM not only protects it from proteasome-mediated degradation but also ensures the full activation of the kinase.
Materials and Methods
Cell culture, antibodies, and expression constructs Cell culture conditions and sources of antibodies as well as all plasmids used are detailed in the Supplementary Information.
Immunoprecipitation and in vitro phosphorylation assays
For all immunoprecipitation experiments cells were lysed in the lysis buffer containing 1% Triton (50 mM Na 2 HPO 4 , 1 mM sodium pyrophosphate, 20 mM NaF, 2 mM EDTA, 2 mM EGTA, 1% Triton X-100, 1 mM DTT, 200 lM benzamidine, 40 lg ml À1 leupeptin, 200 lM PMSF) except where maintaining the integrity of mTOR complexes is required, in which case the lysis buffer containing 0.3% CHAPS instead of 1% Triton X-100 was used [10] . For in vitro phosphorylation of PKCf, endogenous mTORC1 and mTORC2 complexes were immunoprecipitated from the detergentsolubilized 293T cell lysates using the raptor or rictor antibody coupled to protein A/G beads. To generate unphosphorylated PKCf, 293T cells transfected with Flag-PKCf were lysed and immunoprecipitated with anti-Flag agarose, the Flag beads were treated with k-PPase in the phosphatase reaction buffer (50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 2 mM DTT, 0.1 mM EGTA, and 0.01% Brij 35) at 30°C for 1 h to remove phosphates. Dephosphorylated FlagPKCf was eluted from the beads with the Flag peptide, dialyzed, and subsequently used as the substrate. In vitro phosphorylation reactions were initiated by adding the raptor and rictor immunoprecipitates to the dephosphorylated and partially purified FlagPKCf in the kinase buffer (25 mM Tris-HCl, pH7.4, 10 mM MgCl 2 , 5 mM b-glycerophosphate, and 200 lM ATP). Reactions were carried out at 30°C for 30 min and stopped by adding SDS sample buffer.
To assay the kinase activity PKCf, 293T cells transfected with WT and mutant Flag-PKCf were lysed and incubated with anti-Flag agarose. For endogenous PKCf, WT and Ric À/À MEF cell lysates were immunoprecipitated using the anti-PKCf mAb coupled to protein A/G beads. The beads were washed and used as the kinase to phosphorylate myelin basic protein (MBP) as substrate. The kinase reactions were carried out as described above in the kinase buffer containing 5 lg MBP and 10 Ci [c-32 P]ATP. MBP phosphorylation was detected by exposing the membrane to X-ray film and the amount of PKCf was analyzed using immunoblotting.
Ubiquitination and degradation of PKCf
To examine the protein stability of PKCf, cells were pre-treated with HSP90 inhibitor 17-AAG (1 lM) for overnight and subsequently treated with cycloheximide (CHX, 20 lg/ml) or MG-132 (20 lM) as indicated. Specific experimental procedures are described in the Supplementary information.
RhoA/Rac1/Cdc42 activity assays
RhoA and Rac1/Cdc42 activity was assessed using GST-tagged Rhobinding domain of Rhotekin (RBD) and GST-tagged p21 binding domain of PAK1 (GST-PBD), respectively, as described previously [18] . Briefly, cells grown to~70% confluency in regular growth medium were collected in RhoA or Rac1/Cdc42 lysis buffer and cleared extracts were incubated for 30 min at 4°C with glutathione beads coupled with GST-RBD or GST-PBD to pull down activated RhoA or Rac1/Cdc42, respectively. The amount of total and active RhoA, Rac1, and Cdc42 was determined by Western blotting.
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